CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

India's GenAI infrastructure is being built, but can a public-private partnership outpace the trillion-dollar budgets of US ...

The gene editing market is experiencing significant growth, with a projected annual growth rate (CAGR) of 16-18% in the coming years. This expansion is fueled by breakthroughs in gene-editing ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

CRISPR-based diagnostics offer rapid and highly sensitive detection of disease biomarkers. Their ease of use and compatibility with lateral-flow readouts make them suitable for point-of-care ...

When UC Berkeley biochemist Jennifer Doudna first began studying how bacteria fight virus infections, she had no idea it ...

Biomaterials have evolved from passive structural scaffolds to active intelligent systems that dynamically interact with the biological environment. Recent ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

For the scientific enterprise, 2025 was marked by setbacks and challenges. But scientists are no strangers to adversity—the ability to overcome obstacles is built into our training. In turn, research ...

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

India continues to face an alarming rise in air- and water-borne diseases, driven by rapid urbanization, population growth, ...

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...